Fig. 4From: High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysisComparison of the treatment efficacy with onabotulinumtoxinA in patients monomorbid with migraine or depression and patients co-morbid with both disorders. Data of the patients showing only migraine or depression were extracted from the meta-analyses [5, 6, 11, 17]. Data of comorbid patients were calculated based on the studies [18,19,20,21,22,23,24,25]. Comparisons were conducted on patients who have been treated with onabotulinumtoxinA over 3 (BDI and MIDAS) or 6 months (HIT6, VAS and migraine frequency)Back to article page